Loading news...
After losing some value lately, a hammer chart pattern has been formed for AngioDynamics (ANGO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Acuitas Investments LLC grew its holdings in AngioDynamics, Inc. (NASDAQ: ANGO) by 12.7% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 498,530 shares of the medical instruments supplier's stock after purchasing an additional 56,300 shares during the quarter. AngioDynamics comprises 2.4% of
ANGO stock is buoyed by strong fiscal Q2 results, surging NanoKnife adoption in prostate cancer, and broad Med Tech growth supporting margins.
AngioDynamics, Inc. (ANGO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ANGO, BSX and MDT are showing earnings quality improve as higher-margin products take share, supporting margins and durable growth across MedTech.
AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
AngioDynamics reports flat Q2 earnings while revenue increase 8.8% and gross margin expands 170 bps on stronger Med Tech performance.
AngioDynamics (NASDAQ: ANGO) reported fiscal 2026 second-quarter results that management said reflected "strong" execution across the portfolio, with revenue growth and improved profitability. On the company's earnings call, President and CEO Jim Clemmer said the quarter demonstrated AngioDynamics' ability to "drive both revenue growth and profitability simultaneously," and Chief Financial Officer Steve Trowbridge detailed a higher
The medical technology company announced the retirement of CEO Jim Clemmer. This news creates uncertainty for AngioDynamics -- and investors dislike uncertainty.
AngioDynamics, Inc. (ANGO) Q2 2026 Earnings Call Transcript
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2026, which ended November 30, 2025. Fiscal Year 2026 Second Quarter Highlights Quarter Ended November 30, 2025 Pro Forma* YoY Growth Net Sales $.
U.S. stock futures up, focus on AngioDynamics, Microchip Tech, AAR earnings. Galapagos to wind down cell therapy.
U.S. stocks rise on Venezuela raids, Dow hits record high. CNN Money Fear and Greed Index improves but remains in Neutral zone at 46.8.
AngioDynamics, Inc. (NASDAQ: ANGO) will release earnings results for its second quarter before the opening bell on Tuesday, Jan. 6, 2026.
AngioDynamics, Inc. (NASDAQ: ANGO - Get Free Report) shares passed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $10.91 and traded as high as $13.25. AngioDynamics shares last traded at $12.87, with a volume of 228,939 shares changing hands. Wall Street Analysts
AngioDynamics looks undervalued, with Med Tech segment growth in thrombus management, atherectomy, and NanoKnife driving the investment thesis. Consistent execution on revenue growth and margin improvement, especially in Med Tech, is critical for rerating; legacy Med Device business remains a headwind to sentiment. Recent clinical data for AlphaVac and NanoKnife support further adoption, while Auryon continues steady share gains in a competitive atherectomy market.
ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2026 before the market open on Tuesday, January 6, 2026. The Company's management will host a conference call at 8:00 am ET the same day to.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14,.
Delcath Systems (NASDAQ: DCTH - Get Free Report) and AngioDynamics (NASDAQ: ANGO - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability. Valuation and Earnings This table compares Delcath Systems